Login to Your Account

Bydureon and Friends

Regulatory and Commercial Hurdles Test Diabetes Drugs

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, February 6, 2012

Amylin Pharmaceuticals Inc.'s FDA approval of Bydureon (exenatide extended-release) late last month was a long time coming. The company first applied for approval in 2009, requiring three attempts before the FDA finally signed off.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription